Why Supernus Pharmaceuticals Stock Is Rising Today
The company announced positive results from a clinical trial.
Supernus Pharmaceuticals
SUPN
SUPN
$30.94
$1.36
4.6%
Price as of February 24, 2021, 9:00 p.m. EST
View Interactive SUPN Charts
Supernus Pharmaceuticals Inc specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system or CNS diseases.
Interactive Chart
News & Analysis: Supernus Pharmaceuticals
Supernus Pharmaceuticals Inc (SUPN) Q3 2020 Earnings Call Transcript
SUPN earnings call for the period ending September 30, 2020.
3 Small-Cap Stocks With Big-Cap Potential
These stocks are just temporarily inconvenienced large caps in the making.
2 Monster Stocks in the Making
These two biotechs have the potential to become giants within their domains.
Supernus Pharmaceuticals Inc (SUPN) Q2 2020 Earnings Call Transcript
SUPN earnings call for the period ending June 30, 2020.
Supernus Pharmaceuticals Inc (SUPN) Q1 2020 Earnings Call Transcript
SUPN earnings call for the period ending March 31, 2020.
Your 2 Top Profit Opportunities in 2020
These two underrated biotech stocks have the potential to soar.
Why Supernus Pharmaceuticals Plunged 15% Today
Shares slumped after the commercial-stage biopharma reported mixed results.
Supernus Pharmaceuticals Inc (SUPN) Q4 2019 Earnings Call Transcript
SUPN earnings call for the period ending December 31, 2019.
Supernus Pharmaceuticals Inc (SUPN) Q3 2019 Earnings Call Transcript
SUPN earnings call for the period ending September 30, 2019.
